Intrarosa (Prasterone (Dhea)) Patent Expiration, LOE Window & CMS Spending

Intrarosa (Prasterone (Dhea)) by Millicent: FDA Orange Book LOE 2031-03-19, 0 AB generics, $5.0M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMillicent
FDA Application & PathwayN208470 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-03-19
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$5.0M
2024 Medicare Part D Spend$4.3M
2024 Medicaid Spend$656K
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 26.3% 2-yr change)